E. Marshall

发表

In vitro modelling of human tumour behaviour in drug discovery programmes.

B. Baguley, E. Marshall, B C Baguley, 2004, European journal of cancer.

Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

L. Kèlland, B. Baguley, E. Marshall, 2007, Investigational New Drugs.

149 Inhibition of vasculogenic mimicry in melanoma by the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

L. Kèlland, B. Baguley, E. Marshall, 2004 .

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

P. V. van Zijl, B. Baguley, G. Finlay, 1995, European journal of cancer.

Anticancer drug sensitivity profiles of new and established melanoma cell lines.

B. Baguley, G. Finlay, E. Marshall, 1993, Oncology research.

Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.

Claire L. Lill, W. Denny, G. Rewcastle, 2012, Bioorganic & medicinal chemistry.

Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide

B. Baguley, G. Finlay, E. Richardson, 2011, Investigational New Drugs.

Analysis of radiation‐induced changes to human melanoma cultures using a mathematical model

B. Baguley, E. Marshall, B. Basse, 2010, Cell proliferation.

PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression

M. Eccles, B. Baguley, C. Li, 2011, Melanoma research.

Experimental solid tumour activity ofN-[2-(dimethylamino)ethyl]-acridine-4-carboxamide

B. Baguley, E. Marshall, L. Zhuang, 1995, Cancer Chemotherapy and Pharmacology.

Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.

Claire L. Lill, K. Y. Tsang, W. Denny, 2012, Bioorganic & medicinal chemistry.

Therapeutic reactivation of mutant p53 protein by quinazoline derivatives

W. Denny, B. Baguley, E. Richardson, 2012, Investigational New Drugs.

Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110α inhibitors

W. Denny, G. Rewcastle, P. Shepherd, 2007 .

The use of human tumour cell lines in the discovery of new cancer chemotherapeutic drugs

B. Baguley, E. Marshall, 2008, Expert opinion on drug discovery.

In vitro assessment ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance

K. Paull, B. Baguley, G. Finlay, 2004, Cancer Chemotherapy and Pharmacology.

Proliferative assays for the assessment of radiosensitivity of tumor cell lines using 96-well microcultures

W. Wilson, B. Baguley, G. Finlay, 1993 .

Activin is a potent growth suppressor of epithelial ovarian cancer cells.

A. Shelling, B. Baguley, D. Love, 2009, Cancer letters.

Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: synthesis, biological evaluation and molecular modelling.

Claire L. Lill, W. Denny, G. Rewcastle, 2015, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).

Claire L. Lill, S. Gamage, W. Denny, 2011, Journal of medicinal chemistry.

Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.

B. Baguley, L. Ching, K. Mountjoy, 1999, Cancer research.

A Gene Expression Signature of Invasive Potential in Metastatic Melanoma Cells

C. Print, M. Eccles, B. Baguley, 2009, PloS one.

Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases.

W. Denny, G. Rewcastle, B. Baguley, 1998, European journal of cancer.

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations

S. Bohlander, M. Askarian-Amiri, B. Baguley, 2018, Front. Oncol..

Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel

Graeme Wake, Britta Basse, Bruce C. Baguley, 2004, Journal of mathematical biology.

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors

A. Shelling, B. Baguley, G. Finlay, 2013, Front. Genet..

Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma

Euan J. Rodger, C. Print, M. Eccles, 2020, Pigment cell & melanoma research.

Cell cycle times of short-term cultures of brain cancers as predictors of survival

S. Monteith, B. Baguley, C. Sansur, 2008, British Journal of Cancer.

Short-term cultures of clinical tumor material: potential contributions to oncology research.

B. Baguley, G. Finlay, E. Marshall, 1999, Oncology research.

In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma

B. Baguley, G. Finlay, E. Richardson, 2011, Investigational New Drugs.

Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.

B. Baguley, G. Finlay, E. Marshall, 1994, European journal of cancer.

Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines.

B. Baguley, G. Finlay, E. Marshall, 1992, Journal of the National Cancer Institute.

A mathematical model for analysis of the cell cycle in human tumour

G. Wake, B. Brunt, B. Baguley, 2002 .

A mathematical model for analysis of the cell cycle in cell lines derived from human tumors

Graeme Wake, Britta Basse, G. Wake, 2003, Journal of mathematical biology.

Do negative feedback oscillations drive variations in the length of the tumor cell division cycle?

B. Baguley, E. Marshall, 2005, Oncology research.

Estimation of radiation-induced interphase cell death in cultures of human tumor material and in cell lines.

R. Isaacs, B. Baguley, R. Morton, 2004, Oncology Research.

Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitors.

Claire L. Lill, K. Y. Tsang, W. Denny, 2017, Bioorganic & medicinal chemistry letters.

Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: synthesis, biological evaluation and molecular modelling.

Claire L. Lill, W. Denny, G. Rewcastle, 2015, Bioorganic & medicinal chemistry.

Modelling the flow cytometric data obtained from unperturbed human tumour cell lines: Parameter fitting and comparison

Graeme C. Wake, Britta Basse, Bruce C. Baguley, 2005 .

Analysis of radiation‐induced changes to human melanoma cultures using a mathematical model

B. Baguley, E. Marshall, B. Basse, 2010, Cell proliferation.